https://scholars.lib.ntu.edu.tw/handle/123456789/581996
標題: | Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: A multicentre study | 作者: | Dai C.-Y. TAI-CHUNG TSENG Wong G.L.H. Huang J-F. Wong V.W.S. CHUN-JEN LIU Yu M.-L. Chuang W.-L. JIA-HORNG KAO Yuen Chan H.L. DING-SHINN CHEN |
公開日期: | 2013 | 卷: | 68 | 期: | 10 | 起(迄)頁: | 2332-2338 | 來源出版物: | Journal of Antimicrobial Chemotherapy | 摘要: | For hepatitis B e antigen (HBeAg)-positive patients, continuing therapy (consolidation) for 6-12 months before cessation of nucleos(t)ide analogues (NAs) was recommended. This study aimed to investigate whetheralonger period of lamivudine consolidation therapyleads to betteroutcomesandthe clinical factors associated with response. Combined response [HBeAg seroconversion and undetectable serum hepatitis B virus (HBV) DNA by PCR assay]6 months[end of follow-up (EOF)]aftercessation of therapywas assessed in101HBeAg-positivechronically infected patients who received continued long-term lamivudine treatment and achieved a combined response at the end of treatment. The rate of combined response at EOFwas 40.6%. A lower pretreatment HBV DNA level, a longer duration of consolidation therapy, pretreatment hepatitis B surface antigen titre <1500 IU/mL and a higher proportion of consolidation duration of >18 months were significantly associated with combined response. A lower pretreatment HBV DNA level and a longer duration of consolidation therapy were independent factors associated with combined response at EOF by multivariate logistic regression analyses. The rate of combined response was 71.4%, 39.0% and 25.6% in patients with consolidation duration of >18 months, 12-18 months and <12 months, respectively (P=0.001). Consolidation therapy for >18 months achieved a significantly higher rate of combined response at EOF in patients achieving combined response within or after 6 months. Consolidation therapy for >18 months significantly improved the outcome of lamivudine therapy, particularly for patients who achieved a combined response after 6 months. ? The Author 2013. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84888792841&doi=10.1093%2fjac%2fdkt193&partnerID=40&md5=c6c0e24e608287eac0030a5ccaabc819 https://scholars.lib.ntu.edu.tw/handle/123456789/581996 |
ISSN: | 0305-7453 | DOI: | 10.1093/jac/dkt193 | SDG/關鍵字: | hepatitis B surface antigen; hepatitis B(e) antigen; lamivudine; virus DNA; adult; article; clinical feature; drug efficacy; female; follow up; genotype; hepatitis B; human; liver biopsy; liver cirrhosis; long term care; major clinical study; male; multicenter study; predictive value; restriction fragment length polymorphism; retrospective study; seroconversion; treatment duration; treatment response; HBV DNA; hepatitis B e antigen; nucleos(t)ide analogues; Adult; Antiviral Agents; Asian Continental Ancestry Group; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Polymerase Chain Reaction; Retrospective Studies; Treatment Outcome; Viral Load; Young Adult |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。